An evaluation of the rate of nonresponders to latanoprost therapy

Journal of Glaucoma

Volumn 15, Issue 3, 2006, Pages 238-243

  Rossetti, Luca ^a,j   Gandolfi, Stefano ^b   Traverso, Carlo ^c   Montanari, Paolo ^a   Uva, Maurizio ^d   Manni, Gianluca ^e   Carassa, Roberto ^f   Mastropasqua, Leonardo ^g   Quaranta, Luciano ^h   Marchini, Giorgio ⁱ   Ratiglia, Roberto ^a   Orzalesi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g UNIVERSITY OF CHIETI   (Italy)

^h UNIVERSITY OF BRESCIA   (Italy)

ⁱ UNIVERSITY OF VERONA   (Italy)

^j SAN PAOLO HOSPITAL   (Italy)

more..

Author keywords

Glaucoma; Latanoprost; Medical therapy; Ocular hypertension

Indexed keywords

BRIMONIDINE; LATANOPROST; PILOCARPINE; TIMOLOL;

ADULT; APPLICATION SITE BURNING; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRIMARY GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT RESPONSE;

ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DRUG RESISTANCE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PILOCARPINE; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; TIMOLOL; TONOMETRY, OCULAR;

EID: 33745233315     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ijg.0000212214.18018.41     Document Type: Article

References (29)

1. Zang WY, Po AL, Dua HS, et al. A Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open-angle glaucoma. Br J Ophthalmol. 2001; 85:983-990.
2. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol. 2002;47(Suppl 1):S65-S76.
3. Shin DH, McCracken MS, Bendel RE, et al. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy. Ophthalmology. 1999;106: 386-390.
4. Simmons ST, Earl ML, Alphagan/Xalatan Study Group. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology. 2002;109:307-314.
5. Patelska B, Greenfield DS, Liebmann JM, et al. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol. 1997;124:279-286.
6. Kimal AM, Topalkara A, Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol. 1998;22:37-42.
7. Camras CB, Hedman K. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma. 2003; 12:466-469.
8. Choplin N, Bernstein P, Batoosingh AL, et al. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol. 2004;49(Suppl 1):S19-S25.
9. Miglior S, Rossetti L, Brigatti L, et al. Reproducibility of retinal nerve fiber layer evaluation by dynamic scanning laser ophthalmoscopy. Am J Ophthalmol. 1994;118:16-23.
10. Alm A, Widengard I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol. 2000;78:71-76.
11. Fristrom B. A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open-angle glaucoma or ocular hypertension. Acta Ophthalmol. 1996;74: 140-144.
12. O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group. Br J Ophthalmol. 2000;84:579-582.
13. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
14. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110-121.
15. Noecker RS, Dirks MS, Choplin NT, et al. A six-months randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
16. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95-104.
17. Aung T, Chew PT, Yip CC, et al. A randomized double-masked cross-over study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2001;131:636-642.
18. Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol. 2002;18:287-291.
19. Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther. 2002;19:275-281.
20. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47(Suppl 1):S77-S89.
21. Mansberger SL, Passo MS, Schalock PI, et al. Predictive value of a 1-day, 1-eye trial on the one month ocular hypotensive response of latanoprost 0.005%. Am J Ophthalmol. 2001;132:869-871.
22. Kurtz S, Shemesh G. The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure. J Ocul Pharmacol Ther. 2004;20:321-327.
23. Brandt JD, Beiser JA, Gordon MO, et al. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004;138:717-722.
24. Chiba T, Kashiwagi K, Chiba N, et al. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study. Br J Ophthalmol. 2003; 87:956-959.
25. Teus MA, Arranz-Marquez E, Lucea-Suescun P. Incidence of iris colour change in latanoprost treated eyes. Br J Ophthalmol. 2002;86: 1085-1088.
26. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(Suppl 1):S185-S202.
27. Stjernschantz JW, Albert DM, Hu DN, et al. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47(Suppl 1):S62-S75.
28. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138-147.
29. Watson P, Sjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103:126-137.